mirage

Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)

ABACUS/Manakin Repository

Show simple item record

dc.contributor.author Couñago Lorenzo, Felipe
dc.contributor.author Montemuiño, S.
dc.contributor.author Martín, M.
dc.contributor.author Taboada, B.
dc.contributor.author Calvo Crespo, P.
dc.contributor.author Samper Ots, M. P.
dc.contributor.author Alcántara, P.
dc.contributor.author Thuissard Vasallo, Israel John
dc.contributor.author Sanz Rosa, David
dc.contributor.author Dios, N. R. de
dc.contributor.author Et al.
dc.date.accessioned 2018-12-13T16:53:04Z
dc.date.available 2018-12-13T16:53:04Z
dc.date.issued 2018-11-14
dc.identifier.citation Couñago, F., Montemuiño, S., Martin, M., Taboada, B., Calvo-Crespo, P., Samper-Ots, M. P., ... & López-Mata, M. (2018). Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society). Clinical and Translational Oncology, Nov. 14, 1-10. [Epub ahead of print]. https://doi.org/10.1007/s12094-018-1976-3 spa
dc.identifier.issn 1699-048X
dc.identifier.uri http://hdl.handle.net/11268/7695
dc.description.abstract PURPOSE: To evaluate the prognostic factors associated with survival in patients treated with neoadjuvant treatment [chemoradiotherapy (CRT) or chemotherapy] followed by surgery (CRTS) in patients with stage IIIA-N2 non-small cell lung cancer (NSCLC). METHODS: A retrospective study was conducted of 118 patients diagnosed with stage T1-T3N2M0 NSCLC and treated with CRTS at 14 hospitals in Spain between January 2005 and December 2014. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method and compared using the log-rank test. Cox regression analysis was performed. RESULTS: Surgery consisted of lobectomy (74.5% of cases), pneumectomy (17.8%), or bilobectomy (7.6%). Neoadjuvant treatment was CRT in 62 patients (52.5%) and chemotherapy alone in 56 patients (47.5%). Median follow-up was 42.5 months (5-128 months). 5-year OS and PFS were 51.1% and 49.4%, respectively. The following variables were independently associated with worse OS and PFS: pneumonectomy (vs. lobectomy); advanced pathologic T stage (pT3 vs. pT0-pT2); and presence of persistent N2 disease (vs. ypN0-1) in the surgical specimen. CONCLUSIONS: In this sample of patients with stage IIIA-N2 NSCLC treated with CRTS, 5-year survival (both OS and PFS) was approximately 50%. After CRTS, the patients with the best prognosis were those whose primary tumour and/or mediastinal nodal metastases were downstaged after induction therapy and those who underwent lobectomy. These findings provide further support for neoadjuvant therapy followed by surgery in selected patients spa
dc.description.sponsorship SIN FINANCIACIÓN spa
dc.language.iso spa spa
dc.title Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society) spa
dc.type article spa
dc.description.impact 2.392 JCR (2017) Q3, 156/223 Oncology spa
dc.identifier.doi 10.1007/s12094-018-1976-3
dc.rights.accessRights closedAccess spa
dc.subject.uem Cáncer spa
dc.subject.uem Próstata spa
dc.subject.unesco Cáncer spa
dc.description.filiation UEM spa
dc.relation.publisherversion http://ezproxy.universidadeuropea.es/login?url=http:/ /dx.doi.org/10.1007/s12094-018-1976-3 spa
dc.peerreviewed Si spa


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record